Sertraline in Children and Adolescents With Major Depressive Disorder

Donnelly, Craig L.; Wagner, Karen Dineen; Rynn, Moira A.; Ambrosini, Paul J.; Landau, Phyllis; Yang, Ruoyong; Wohlberg, Christopher J.

doi:10.1097/01.chi.0000233204.51050.f0

Cited by 19 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All together, the studies included 2533 patients in placebo arms (N = 1528 in MDD, N = 371 in OCD, N = 634 in AD-non-OCD). Thirty studies were excluded from the analysis because of cross-over (or other) design [33]–[40], non-dichotomized definition of responders or absence of specific data [41]–[43], placebo arms with fewer than 10 patients [44]–[46], data reported elsewhere or re-analysis of previous report [25], [47]–[53], or lack of placebo arm [54]–[59]. Finally, Berstein and colleagues' studies [16], [60] were excluded because all patients had AD comorbid with MDD.…”

Section: Resultsmentioning

confidence: 99%

Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials

et al. 2008

View full text Add to dashboard Cite

BackgroundIn a previous report, we hypothesized that responses to placebo were high in child and adolescent depression because of specific psychopathological factors associated with youth major depression. The purpose of this study was to compare the placebo response rates in pharmacological trials for major depressive disorder (MDD), obsessive compulsive disorder (OCD) and other anxiety disorders (AD-non-OCD).Methodology and Principal FindingsWe reviewed the literature relevant to the use of psychotropic medication in children and adolescents with internalized disorders, restricting our review to double-blind studies including a placebo arm. Placebo response rates were pooled and compared according to diagnosis (MDD vs. OCD vs. AD-non-OCD), age (adolescent vs. child), and date of publication. From 1972 to 2007, we found 23 trials that evaluated the efficacy of psychotropic medication (mainly non-tricyclic antidepressants) involving youth with MDD, 7 pertaining to youth with OCD, and 10 pertaining to youth with other anxiety disorders (N = 2533 patients in placebo arms). As hypothesized, the placebo response rate was significantly higher in studies on MDD, than in those examining OCD and AD-non-OCD (49.6% [range: 17–90%] vs. 31% [range: 4–41%] vs. 39.6% [range: 9–53], respectively, ANOVA F = 7.1, p = 0.002). Children showed a higher stable placebo response within all three diagnoses than adolescents, though this difference was not significant. Finally, no significant effects were found with respect to the year of publication.ConclusionMDD in children and adolescents appears to be more responsive to placebo than other internalized conditions, which highlights differential psychopathology.

show abstract

Section: Resultsmentioning

confidence: 99%

Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Hemos querido comprobar si en los años posteriores a la alerta se han realizado estudios que aporten nueva información sobre efi cacia de antidepresivos en menores de 18 años que permitan replantearse estas conclusiones. En la tabla 1 se detallan las principales características de los 7 estudios publicados desde el año 1990 hasta el año 2003 y los 12 nuevos publicados desde 2004 hasta 2010 24,[26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43] . De los siete ECA publicados antes de la alerta en 2003, seis comparan fármaco con placebo 24,26,27,34,35,42 y uno compara paroxetina con imipramina 31 SI (CGI, p = 0,02; CDRS-R, p = 0,01).…”

Section: Evidencia De Efi Cacia De Los Antidepresivos En Niños Y Adolunclassified

“…De los ocho ECA realizados en fase aguda, dos (1 citalopram, 1 escitalopram) demostraron mayor efi cacia versus placebo con signifi cación estadística 37,41 . Donelly y cols (2006), en un estudio diseñado para diferenciar resultados por grupos de edad, obtuvieron signifi cativamente mayor respuesta en el mantenimiento con sertralina versus placebo, aunque sólo en adolescentes (12-17 años) (p = 0,022) 36 . Aunque los estudios de Wagner y cols (2006), con escitalopram y de Emslie y cols (2007), con venlafaxina también sugieren mayor efi cacia frente a placebo (p = 0,047 y p = 0,022 respectivamente) en este grupo de edad, no fueron diseñados a priori para el análisis de las diferencias de resultados entre niños y adolescentes 40,43 .…”

Section: Diferencias Nsunclassified

“…En resumen, de los 14 ECA seleccionados entre 1990 y 2010, solo 1 publicado previamente a las alertas 2003 de Seguridad (fl uoxetina) 24 y dos con posterioridad a las mismas (1 citalopram, 1 escitalopram) 37,41 , aportan evidencias signifi cativas de mayor efi cacia versus placebo en el tratamiento en fase aguda del trastorno depresivo mayor en población infanto-juvenil y el estudio de Sertralina de Donelly y cols. (2006) también demostró efi cacia en el grupo de edad comprendido entre 12-17 años 36 .…”

Section: Diferencias Nsunclassified

See 1 more Smart Citation

Riesgo de suicidio en población pediátrica tratada con antidepresivos: impacto de la alerta de 2003 en la prescripción e investigación en eficacia y seguridad

2011

Rev. chil. pediatr.

View full text Add to dashboard Cite

“…Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) were used to assess global mental health [32]. Data were typically reported in the main study publication, but in three instances, data were extracted from secondary papers which were more focused on patient-rated outcomes than were the primary study publications [33,34,35]. …”

Section: Methodsmentioning

confidence: 99%

The Efficacy of Antidepressants on Overall Well-Being and Self-Reported Depression Symptom Severity in Youth: A Meta-Analysis

Spielmans

Gerwig²

2014

Psychother Psychosom

View full text Add to dashboard Cite

Background: Recent meta-analyses of the efficacy of second-generation antidepressants for youth have concluded that such drugs possess a statistically significant advantage over placebo in terms of clinician-rated depressive symptoms. However, no meta-analysis has included measures of quality of life, global mental health, self-esteem, or autonomy. Further, prior meta-analyses have not included self-reports of depressive symptoms. Methods: Studies were selected through searching Medline, PsycINFO, and the Cochrane Central Register for Controlled Trials databases as well as GlaxoSmithKline's online trial registry. We included self-reports of depressive symptoms and pooled measures of quality of life, global mental health, self-esteem, and autonomous functioning as a proxy for overall well-being. Results: We found a nonsignificant difference between second-generation antidepressants and placebo in terms of self-reported depressive symptoms (k = 6 trials, g = 0.06, p = 0.36). Further, pooled across measures of quality of life, global mental health, self-esteem, and autonomy, antidepressants yielded no significant advantage over placebo (k = 3 trials, g = 0.11, p = 0.13). Discussion: Though limited by a small number of trials, our analyses suggest that antidepressants offer little to no benefit in improving overall well-being among depressed children and adolescents.

show abstract

Sertraline in Children and Adolescents With Major Depressive Disorder

Cited by 19 publications

References 21 publications

Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials

Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials

Riesgo de suicidio en población pediátrica tratada con antidepresivos: impacto de la alerta de 2003 en la prescripción e investigación en eficacia y seguridad

The Efficacy of Antidepressants on Overall Well-Being and Self-Reported Depression Symptom Severity in Youth: A Meta-Analysis

Contact Info

Product

Resources

About